Recent findings from a substudy of DETOUR2 demonstrated that percutaneous transmural arterial bypass (PTAB) may offer an ...
A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...
A long-standing request to clarify data irregularities in a 2021 ISCHEMIA substudy resulted in the publication of one correction, with a second correction in the works. Further, the lone cardiac ...
CHICAGO, IL—When patients stop taking oral anticoagulation (OAC) after they’ve been free of atrial fibrillation (AF) ...
Please provide your email address to receive an email when new articles are posted on . In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ...
BASKING RIDGE, N.J. -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced the presentation of two posters ...
New findings from a DETOUR2 substudy show that minimally invasive percutaneous transmural arterial bypass (PTAB) may offer a ...
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing ...
Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results